The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://tomasdxwm007955.blog5star.com/39465474/glp-3-retatrutide-a-comparative-analysis